Where botulinum toxin works, and where it stops

Why can the same class of medicine do different jobs?

Botulinum toxin type A interferes with the release of chemical messages from nerve endings. It cuts a protein called SNAP-25, which helps small packets of signalling chemicals merge with the nerve's outer membrane and release their contents. ^[1]

At the junction between a nerve and a muscle, less of the messenger acetylcholine is released, so the muscle contracts less. At nerves supplying sweat glands, reducing acetylcholine release reduces sweating. ^[1][2]

The explanation for migraine involves sensory nerves and pain signalling. Research suggests that reducing the release of substances such as CGRP helps interrupt the processes that make these nerves overly sensitive. The full clinical mechanism is still being investigated; relaxing muscle alone does not adequately explain the benefit. ^[1]

This is why an explanation based entirely on relaxing facial muscles misses much of the medicine's work. It is also why the name of a medicine is not enough to tell you what a particular treatment can achieve.

What does a successful treatment mean?

The answer changes with the problem being treated. A reduction in sweating is not the same outcome as fewer migraine days or a change in the appearance of a line. The following examples come from specific studies and products; their percentages should not be used to rank the uses against one another.

Frown lines

In the manufacturer’s UK product information for one preparation, investigators rated frown lines as absent or mild at maximum frown in 325 of 405 treated participants (80%), compared with 4 of 132 receiving placebo (3%), 30 days after injection. These participants had started with moderate or severe lines. The product information separately summarises treatment-related adverse events in controlled frown-line trials: 23% with medicine and 19% with placebo; it does not state the safety denominator alongside those rates. ^[3]

That measures a visible change in a particular line at a particular time. It does not mean that 80% became younger, that every line disappeared, or that the effect was permanent.

How long does the change last?

The effect is temporary. In a 264-person frown-line trial, improvement was still present in many participants at day 120, when follow-up ended. The study did not measure when every result wore off, and it does not establish a single duration for every patient or every use. ^[9]

Underarm sweating

A randomised trial included 320 adults whose sweating interfered with daily life. At four weeks, measured sweat production had fallen by at least half in 227 of 242 treated participants (94%), compared with 28 of 78 given placebo (36%). At 16 weeks the corresponding figures were 82% and 21%. ^[4]

Treatment-related adverse events were reported by 27 of 242 treated participants (11%) and 4 of 78 receiving placebo (5%); the study did not establish a statistically clear difference in that safety measure. Thirteen participants did not complete follow-up; missing results used the last recorded measurement. The manufacturer funded the trial, and the authors disclosed financial connections. ^[4]

The result supports a reduction in underarm sweating in people like those studied. It does not show that everyone becomes completely dry, or that sweating elsewhere will respond in the same way.

Chronic migraine

The Cochrane review's analysis excluding small trials estimated about two fewer migraine days per month than placebo at 12 weeks. It involved 1,384 participants from the two PREEMPT trials, with an estimated range of 1.1–2.8 fewer days. This is a re-analysis of those trials, not a separate new group of patients. ^[5]

Some people improve substantially, while others do not obtain a worthwhile benefit. The dedicated chronic migraine article explains the response targets, side effects, medication-overuse findings and alternatives, including other preventive medicines. When headache takes over the month

A licence belongs to a product and a use

A UK medicine licence sets out the circumstances in which its benefits have been judged to outweigh its risks. Those terms include the condition, dose and patient group. A licence for one use does not approve every use of that medicine. ^[6]

Off-label prescribing means using a licensed medicine outside those terms. It can be a justified clinical decision, but requires supporting evidence, an explanation of the reasons and appropriate monitoring. An unlicensed product is a different issue: the product itself lacks a UK marketing authorisation. These terms should not be treated as interchangeable. ^[6]

A useful question is: “Is this particular product licensed for what you are proposing, and what evidence supports the plan if it is not?” The answer should be specific enough for you to understand the decision.

Different products also have different units. A unit count from one preparation cannot simply be transferred to another. Keep the product name with your treatment record. ^[3]

What the medicine does not replace

An effect on nerve signalling does not supply missing volume or replace bone. Changing muscle activity may alter the position or contour of a feature, but a description such as “lifting” needs to say what is actually expected to move and by how much.

Lines visible at rest can improve too; the frown-line trial also assessed them. That does not make every static line a suitable target or mean every skin concern has the same cause. ^[9]

A photograph can show an appearance. It cannot tell you which part of a treatment produced it, how long it lasted, or what happened in people whose results were less favourable. Those questions need more than a gallery.

Risk needs to be discussed for the actual treatment

The site, dose, product and your health affect the risk. The UK regulator warns that serious effects can occur if toxin acts beyond the intended area. Risk may be greater with underlying neurological or swallowing problems, higher doses, off-label use or unauthorised products. A licensed product still requires careful prescribing and administration. ^[7]

New difficulty breathing, swallowing or speaking after treatment needs immediate emergency medical help. Symptoms of iatrogenic botulism can develop up to four weeks after treatment. The MHRA warning applies to medical and cosmetic use. ^[7]

Previous treatment without problems does not rule out a reaction to a later treatment. Infection at an injection site or an allergy to the preparation can prevent treatment. Pregnancy, breastfeeding and existing nerve–muscle conditions require specific assessment. ^[3]

In England, the law restricts cosmetic botulinum toxin treatment in under-18s; parental permission does not remove that restriction. The statutory exception requires approval by a registered doctor and administration by a registered doctor, nurse, pharmacist or dentist. ^[8]

What should you leave an assessment knowing?

You should understand the specific problem being treated, what improvement would count as worthwhile, and when the result will be reviewed. You should also know the alternatives, including leaving things as they are, and who to contact if something goes wrong.

I would want the proposed benefit to be clear enough to recognise afterwards. If the explanation is only that something will look “better”, there is still a conversation to have.